Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03863080 · ClinicalTrials.gov registry record · Phase 2
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
A Phase 2 study of Myasthenia Gravis, sponsored by Immunovant Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 20
- Study locations
NCT03863080 is a Phase 2 study of Myasthenia Gravis that has completed, run by Immunovant Sciences. The registered enrollment target is 17 participants, below the 191-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT03863080, a Phase 2 study of Myasthenia Gravis, has completed, sponsored by Immunovant Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compared to placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RVT-1401
Study Locations (20)
California
- The Neurology Center of Southern California - Carlsbad
- UC Irvine - MDA ALS and Neuromuscular Center - Orange
- Care Access Research - Pasadena
New York
- Dent Institute - Amherst
- University of Buffalo - Buffalo
- Hospital for Special Surgery - New York
Ontario
- London Health Sciences Centre - London
- Ottawa Hospital Research Institute - Ottawa
- University Health Network Toronto General Hospital - Toronto
Alabama
- IMC/Diagnostic and Medical Clinic - Mobile
Arizona
- Phoenix Neurological Associates - Phoenix
Colorado
- CSNA - Colorado Springs
Connecticut
- Yale School of Medicine Department of Neurology - New Haven
Florida
- Neurological Services of Orlando - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-05-21 |
| Est. Completion | 2020-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03863080
The ClinicalTrials.gov registry entry for NCT03863080 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 191-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (91% lower). The listed sponsor is Immunovant Sciences, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03863080 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, New York, Ontario.
Frequently Asked Questions
What is clinical trial NCT03863080 about?
NCT03863080 is a clinical study titled "A Study of RVT-1401 in Myasthenia Gravis (MG) Patients". The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compa...
What is the current status of trial NCT03863080?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2019-05-21. Estimated completion is 2020-12-21.
What conditions does trial NCT03863080 study?
This clinical trial studies the following conditions: Myasthenia Gravis.
What interventions are being tested in trial NCT03863080?
The interventions under investigation include: Placebo (DRUG), RVT-1401 (DRUG).
Who is sponsoring clinical trial NCT03863080?
This trial is sponsored by Immunovant Sciences, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03863080 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
RECRUITING · Phase 2
-
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
RECRUITING · Phase 2
-
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
COMPLETED · Phase 2
-
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.